{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T04:07:18Z","timestamp":1791086838012,"version":"4.1.0"},"reference-count":30,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2001,12,24]],"date-time":"2001-12-24T00:00:00Z","timestamp":1009152000000},"content-version":"vor","delay-in-days":541,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2000,7]]},"abstract":"<jats:p>We evaluated the outcome of allogeneic bone marrow transplantation (BMT) in 21 patients with chronic myelomonocytic leukaemia (CMML) who were treated at the Fred Hutchinson Cancer Research Center between 1990 and 1998. There were 11 male and 10 female patients with a median age of 47\u00b74\u2003years (range 1\u00b70\u201362\u00b79). Patients were conditioned either with total body irradiation (TBI) and chemotherapy, with or without antithymocyte globulin (<jats:italic>n<\/jats:italic>\u2003=\u200319), or with chemotherapy alone (<jats:italic>n<\/jats:italic>\u2003=\u20032). The marrow donor was an HLA\u2010identical sibling in 12 patients, an HLA\u2010non\u2010identical related donor in three patients and an unrelated volunteer donor in six patients. All evaluable patients achieved sustained engraftment. Fifteen patients developed grades II\u2013IV acute graft\u2010versus\u2010host disease (GVHD). Nine patients (43\u00b70%) are surviving disease free at 0\u00b77\u20138\u00b71\u2003years (median 6\u00b79) after transplantation. Five patients relapsed 75\u2013660\u2003d after transplant and all died. Five patients died with organ failure and two died with GVHD and associated infections. The Kaplan\u2013Meier estimates of disease\u2010free survival and relapse at 3\u2003years were 39% and 25% respectively. The probability of survival was improved in patients with shorter disease duration compared with those with a long interval from diagnosis to BMT. Thus, as with other myeloproliferative diseases or myelodysplastic syndromes, BMT offers curative therapy for a proportion of patients with CMML. We suggest that patients with CMML who have a suitable donor should be considered for transplantation, probably early in their disease course. However, it will be important to develop new regimens with enhanced antileukaemic efficacy without further increasing regimen\u2010related toxicity and mortality.<\/jats:p>","DOI":"10.1046\/j.1365-2141.2000.02133.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T06:25:46Z","timestamp":1047363946000},"page":"217-222","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Treatment of chronic myelomonocytic leukaemia by allogeneic marrow transplantation"],"prefix":"10.1111","volume":"110","author":[{"given":"Dae Young","family":"Zang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Joachim","family":"Deeg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ted","family":"Gooley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne E.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Anasetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Sanders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Myerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Storb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Appelbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2001,12,24]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.1.220"},{"key":"e_1_2_6_3_1","first-page":"S25","article-title":"Allogeneic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to IPSS score","volume":"12","author":"Appelbaum F.R.","year":"1998","journal-title":"Leukemia"},{"key":"e_1_2_6_4_1","first-page":"405","article-title":"Bone marrow transplantation for chronic myelogenous leukemia (Review)","volume":"22","author":"Appelbaum F.R.","year":"1995","journal-title":"Seminars in Oncology"},{"key":"e_1_2_6_5_1","first-page":"443","article-title":"Multivariate analysis of risk factors for survival and relapse in chronic granulocytic leukemia following allogeneic marrow transplantation: impact of disease related variables","volume":"12","author":"Bacigalupo A.","year":"1993","journal-title":"Bone Marrow Transplantation"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428199909058471"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1982.tb02771.x"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1994.tb06734.x"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.7.2473.bloodjournal8872473"},{"key":"e_1_2_6_10_1","first-page":"1164","article-title":"All\u2010trans retinoic acid in adult chronic myelomonocytic leukemia: results of a pilot study","volume":"10","author":"Cambier N.","year":"1996","journal-title":"Leukemia"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00282-997-0041-4"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1986.4.12.1857"},{"key":"e_1_2_6_13_1","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life\u2010tables (with discussions), Series B","volume":"34","author":"Cox D.R.","year":"1972","journal-title":"Journal of the Royal Statistical Society"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.10.3880"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1987.tb06142.x"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1988.6.9.1417"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1991.tb08616.x"},{"key":"e_1_2_6_18_1","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1182\/blood.V82.7.2235.2235","article-title":"Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase","volume":"82","author":"Goldman J.M.","year":"1993","journal-title":"Blood"},{"key":"e_1_2_6_19_1","first-page":"509","article-title":"Bone marrow transplantation for chronic myeloid leukemia: long\u2010term results. Chronic leukemia working party of the European group for bone marrow transplantation","volume":"12","author":"Gratwohl A.","year":"1993","journal-title":"Bone Marrow Transplantation"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.6.2079"},{"key":"e_1_2_6_21_1","volume-title":"The Statistical Analysis of Failure Time Data.","author":"Kalbfleisch J.D.","year":"1980"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428199309148501"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.9.3634.bloodjournal8893634"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.10.3515"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198603203141201"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(12)61287-7"},{"key":"e_1_2_6_28_1","first-page":"807","volume-title":"Hematopoietic Cell Transplantation","author":"Thomas E.D.","year":"1999"},{"key":"e_1_2_6_29_1","first-page":"258","article-title":"Diagnosis, classification, and cytogenetics of myelodysplastic syndromes (Review)","volume":"83","author":"Vallespi T.","year":"1998","journal-title":"Haematologica"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.7.2480.bloodjournal8872480"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1988.tb04173.x"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2141.2000.02133.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2141.2000.02133.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2141.2000.02133.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,7]],"date-time":"2024-12-07T13:29:02Z","timestamp":1733578142000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2141.2000.02133.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,7]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2000,7]]}},"alternative-id":["10.1046\/j.1365-2141.2000.02133.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2141.2000.02133.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,7]]},"assertion":[{"value":"2001-12-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}